 This is a phase Ib study with the primary objectives of determining the safety and tolerability as well as pharmacokinetics after single ascending doses SAD and multiple ascending doses MAD of RQ10 in Parkinsons disease patients. A secondary objective will be to assess the impact of single doses of RQ10 on gastric emptying in Parkinsons Disease patients as well as the effects of RQ10 on gastroparesis symptoms. The expected results of this exploratory phase Ib study will allow deciding about whether to proceed with further development of RQ10 in Parkinsons Disease patients go-no go and help design a formal phase IIa proof of concept study by informing repeat-dose selection and possible effect sizes in Parkinsons Disease patients. 